FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026200435> ?p ?o ?g. }

• W2026200435 endingPage "224" @default.
• W2026200435 startingPage "218" @default.
• W2026200435 abstract "New anticoagulants have been designed using advances in the biotechnology and the biochemistry of the clotting factors. They are classified according to their target or their mechanism of action (AT-dependent or AT-independent). Antithrombotic activity after oral administration is another important property. This abstract is restricted to the synthetic pentasaccharide and the ximelagatran/melagatran. Fondaparinux (Arixtra) is a chemically synthesized methoxy derivative of the natural pentasaccharide (MW=1728 Da). Fondaparinux has nearly complete bioavailabity after subcutaneous injection. The elimination half-life is about 17 hours. Fondaparinux is cleared from the kidneys. In contrast to heparin, fondaparinux does not interact with plasma proteins other than antithrombin and it does not cross-react in vitro with heparin induced thrombocytopenia antibodies. Fondaparinux inhibits specifically FXa, although some other targets are suspected (FIXa and FVIIa). Endogenous levels of AT are the rate limiting factor for its anti-Xa activity. Fondaparinux, in contrast to direct FXa inhibitors (i.e. DX-9065a) inhibits free FXa but not the FXa bound to prothrombinase, and it does not prolong PT and aPTT. Fondaparinux inhibits thrombin generation in human plasma. We have shown that the inhibition of thrombin generation by fondaparinux is inversely correlated with thromboplastin concentration. This original observation may explain the absence of any effect of fondaparinux on PT. Melagatran dipeptide (MW=430 Da) is a specific, reversible direct thrombin inhibitor. It inhibits free and clot bound thrombin. Its half-life is 1.7-2.5 hours after i.v. or s.c. administration. Ximelagatran (Exantas), is a pro-drug with a hydroxyamidino instead of amidino-group and an esterified carboxyl-group. It is the first clinically used direct orally acting thrombin inhibitor. Ximelagatran after intestinal absorption is metabolized to melagatran. Melagatran is not metabolized and is cleared through the kidney. Among the specific FXa inhibitors the synthetic pentasaccharide (Fondaparinux-Arixtra) has been approved by FDA and several European health organizations for the prophylaxis of VTE in major orthopedic surgery. No specific antidote has been described for the new antithrombotics. Encouraging results have been obtained from our group on the possible use of rFVIIa (Novoseven). The general opinion is that there is no need for laboratory monitoring of the new antithrombotic agents. Conclusion. The research for safer and more effective anticoagulants has been successful by targeting specific steps in coagulation. These single-targeted agents are challenging multi-targeted drugs (heparins and vitamin-K antagonists). Other drugs including orally active FXa direct inhibitors will probably enrich the armentarium of antithrombotic drugs." @default.
• W2026200435 created "2016-06-24" @default.
• W2026200435 creator A5039696885 @default.
• W2026200435 creator A5043034719 @default.
• W2026200435 creator A5052996125 @default.
• W2026200435 creator A5076290258 @default.
• W2026200435 creator A5084062066 @default.
• W2026200435 date "2002-01-01" @default.
• W2026200435 modified "2023-10-06" @default.
• W2026200435 title "Biochemistry and clinical pharmacology of new anticoagulant agents" @default.
• W2026200435 cites W1628030746 @default.
• W2026200435 cites W164295419 @default.
• W2026200435 cites W1833703938 @default.
• W2026200435 cites W1834684491 @default.
• W2026200435 cites W1970619525 @default.
• W2026200435 cites W1977434798 @default.
• W2026200435 cites W1981389135 @default.
• W2026200435 cites W2021322314 @default.
• W2026200435 cites W2024270349 @default.
• W2026200435 cites W2055134408 @default.
• W2026200435 cites W2060202760 @default.
• W2026200435 cites W2065683881 @default.
• W2026200435 cites W2081128771 @default.
• W2026200435 cites W2082730110 @default.
• W2026200435 cites W2091027505 @default.
• W2026200435 cites W2099094229 @default.
• W2026200435 cites W2124852408 @default.
• W2026200435 cites W2141373630 @default.
• W2026200435 cites W2152027086 @default.
• W2026200435 cites W2162356386 @default.
• W2026200435 cites W2168156414 @default.
• W2026200435 cites W2401530070 @default.
• W2026200435 cites W2415536241 @default.
• W2026200435 cites W2416632942 @default.
• W2026200435 doi "https://doi.org/10.1159/000073570" @default.
• W2026200435 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/13679646" @default.
• W2026200435 hasPublicationYear "2002" @default.
• W2026200435 type Work @default.
• W2026200435 sameAs 2026200435 @default.
• W2026200435 citedByCount "38" @default.
• W2026200435 countsByYear W20262004352012 @default.
• W2026200435 countsByYear W20262004352013 @default.
• W2026200435 countsByYear W20262004352014 @default.
• W2026200435 crossrefType "journal-article" @default.
• W2026200435 hasAuthorship W2026200435A5039696885 @default.
• W2026200435 hasAuthorship W2026200435A5043034719 @default.
• W2026200435 hasAuthorship W2026200435A5052996125 @default.
• W2026200435 hasAuthorship W2026200435A5076290258 @default.
• W2026200435 hasAuthorship W2026200435A5084062066 @default.
• W2026200435 hasConcept C112516734 @default.
• W2026200435 hasConcept C126322002 @default.
• W2026200435 hasConcept C144594695 @default.
• W2026200435 hasConcept C185592680 @default.
• W2026200435 hasConcept C203014093 @default.
• W2026200435 hasConcept C2776301958 @default.
• W2026200435 hasConcept C2776877702 @default.
• W2026200435 hasConcept C2777015399 @default.
• W2026200435 hasConcept C2777292125 @default.
• W2026200435 hasConcept C2777557582 @default.
• W2026200435 hasConcept C2778205648 @default.
• W2026200435 hasConcept C2778382381 @default.
• W2026200435 hasConcept C2778810321 @default.
• W2026200435 hasConcept C2779026020 @default.
• W2026200435 hasConcept C2779161974 @default.
• W2026200435 hasConcept C2779630707 @default.
• W2026200435 hasConcept C2780205058 @default.
• W2026200435 hasConcept C2780868729 @default.
• W2026200435 hasConcept C2991741193 @default.
• W2026200435 hasConcept C55493867 @default.
• W2026200435 hasConcept C57002609 @default.
• W2026200435 hasConcept C71924100 @default.
• W2026200435 hasConcept C89560881 @default.
• W2026200435 hasConcept C98274493 @default.
• W2026200435 hasConceptScore W2026200435C112516734 @default.
• W2026200435 hasConceptScore W2026200435C126322002 @default.
• W2026200435 hasConceptScore W2026200435C144594695 @default.
• W2026200435 hasConceptScore W2026200435C185592680 @default.
• W2026200435 hasConceptScore W2026200435C203014093 @default.
• W2026200435 hasConceptScore W2026200435C2776301958 @default.
• W2026200435 hasConceptScore W2026200435C2776877702 @default.
• W2026200435 hasConceptScore W2026200435C2777015399 @default.
• W2026200435 hasConceptScore W2026200435C2777292125 @default.
• W2026200435 hasConceptScore W2026200435C2777557582 @default.
• W2026200435 hasConceptScore W2026200435C2778205648 @default.
• W2026200435 hasConceptScore W2026200435C2778382381 @default.
• W2026200435 hasConceptScore W2026200435C2778810321 @default.
• W2026200435 hasConceptScore W2026200435C2779026020 @default.
• W2026200435 hasConceptScore W2026200435C2779161974 @default.
• W2026200435 hasConceptScore W2026200435C2779630707 @default.
• W2026200435 hasConceptScore W2026200435C2780205058 @default.
• W2026200435 hasConceptScore W2026200435C2780868729 @default.
• W2026200435 hasConceptScore W2026200435C2991741193 @default.
• W2026200435 hasConceptScore W2026200435C55493867 @default.
• W2026200435 hasConceptScore W2026200435C57002609 @default.
• W2026200435 hasConceptScore W2026200435C71924100 @default.
• W2026200435 hasConceptScore W2026200435C89560881 @default.
• W2026200435 hasConceptScore W2026200435C98274493 @default.
• W2026200435 hasIssue "5-6" @default.

• next